MARATTO

article · BMC Microbiology

Fecal carriage of resistant Escherichia coli in livestock in Algeria: emergence of NDM and OXA-181

Abstract

The spread of third-generation cephalosporin (3GC)-resistant Escherichia coli in food-producing animals poses a significant threat to public health, with limited data from cattle and sheep in Algeria. This study investigated the prevalence of 3GC-resistant E. coli in cattle and sheep in Guelma, northeast Algeria. Two hundred eighty-five fecal samples were collected from cattle (n=145) and sheep (n=140) on 28 farms. Samples were screened for 3GC-resistant E. coli. Antibiotic susceptibility was tested, and ESBL and carbapenemase production were evaluated using double disc and EDTA tests. PCR identified resistance and integron genes. Twenty-seven cefotaxime-resistant E. coli isolates were detected in 17% of bovine and 1% of ovine samples, spanning 43% of the farms. Multidrug resistance was observed in 85% of isolates, with high resistance to β-lactams, tetracyclines, fluoroquinolones, and trimethoprim-sulfamethoxazole. The following beta-lactamase genes were detected: blaCTX-M (74%), blaCMY (44%), blaNDM-1 (37%), and blaOXA-181 (4%) were identified. Class 1 integrons were also detected in ten isolates. These findings emphasize the presence of ESBL-, AmpC-, and carbapenemase-producing E. coli among Algerian livestock, highlighting the need for comprehensive monitoring and control to manage the spread of these resistant bacteria.

Research topics

  • Escherichia coli research studies
  • Antibiotic Resistance in Bacteria
  • Vibrio bacteria research studies

Sustainable Development Goals

Read the original research

This page summarises published work. The authoritative version sits with the publisher.

DOI: 10.1186/s12866-025-04174-2

Is something wrong with this record? Report it or request removal.

Discussion

Discuss this research

Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.

No discussion yet. Open the first thread.